Alterations in Fecal Short Chain Fatty Acids (SCFAs) and Branched Short-chain Fatty Acids (BCFAs) in Men with Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS)

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Apr 13

PMID 33847600

Citations 18

Authors

Weronika Ratajczak

Arnold Mizerski

Aleksandra Ryl

Marcin Slojewski

Olimpia Sipak

Malgorzata Piasecka

Maria Laszczynska

Affiliations

Soon will be listed here.

Abstract

Gut microbiome-derived short-chain fatty acids (SCFAs) emerge in the process of fermentation of polysaccharides that resist digestion (dietary fiber, resistant starch). SCFAs have a very high immunomodulatory potential and ensure local homeostasis of the intestinal epithelium, which helps maintain the intestinal barrier. We analyzed the association between stool SCFAs levels acetic acid (C 2:0), propionic acid (C 3:0), isobutyric acid (C 4:0i), butyric acid (C 4:0n), isovaleric acid (C 5:0i) valeric acid (C 5:0n), isocaproic acid (C 6:0i), and caproic acid (C 6:0n)) in aging man with benign prostatic hyperplasia (BPH) and healthy controls. The study involved 183 men (with BPH, n = 103; healthy controls, n = 80). We assessed the content of SCFAs in the stool samples of the study participants using gas chromatography. The levels of branched SCFAs (branched-chain fatty acids, BCFAs): isobutyric acid (C4:0i) (p = 0.008) and isovaleric acid (C5:0i) (p < 0.001) were significantly higher in patients with BPH than in the control group. In healthy participants isocaproic acid (C6:0i) predominated (p = 0.038). We also analyzed the relationship between stool SCFA levels and serum diagnostic parameters for MetS. We noticed a relationship between C3:0 and serum lipid parameters (mainly triglycerides) in both healthy individuals and patients with BPH with regard to MetS. Moreover we noticed relationship between C4:0i, C5:0i and C6:0i and MetS in both groups. Our research results suggest that metabolites of the intestinal microflora (SCFAs) may indicate the proper function of the intestines in aging men, and increased BCFAs levels are associated with the presence of BPH.

Citing Articles

Circulating short-chain and branched short-chain fatty acids and the risk of incident type 2 diabetes: findings from the 4C study.

Wang S, Lin H, Jia X, Lin Y, Hu C, Li M Life Metab. 2025; 4(2):loaf001.

PMID: 40078932 PMC: 11897982. DOI: 10.1093/lifemeta/loaf001.

Analysis of the Beneficial Effects of Probiotics on the Gut-Prostate Axis Using Prostatic Co-Culture Model.

Ferrari S, Galla R, Mule S, Uberti F Foods. 2024; 13(22).

PMID: 39594064 PMC: 11593767. DOI: 10.3390/foods13223647.

Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization.

Cui Y, Wang H, Wang Y Sci Rep. 2024; 14(1):26152.

PMID: 39478098 PMC: 11525667. DOI: 10.1038/s41598-024-77515-2.

The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications.

Chen J, Chen B, Lin B, Huang Y, Li J, Li J Heliyon. 2024; 10(19):e38302.

PMID: 39386817 PMC: 11462338. DOI: 10.1016/j.heliyon.2024.e38302.

Gut microbiome: a novel preventive and therapeutic target for prostatic disease.

Cao H, Zhang D, Wang P, Wang Y, Shi C, Wu H Front Cell Infect Microbiol. 2024; 14:1431088.

PMID: 39135640 PMC: 11317475. DOI: 10.3389/fcimb.2024.1431088.

References

Mizuno M, Noto D, Kaga N, Chiba A, Miyake S . The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS One. 2017; 12(2):e0173032. PMC: 5325617. DOI: 10.1371/journal.pone.0173032. View

Amieva M, Vogelmann R, Covacci A, Tompkins L, Nelson W, Falkow S . Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science. 2003; 300(5624):1430-4. PMC: 3369828. DOI: 10.1126/science.1081919. View

Roelofsen H, Priebe M, Vonk R . The interaction of short-chain fatty acids with adipose tissue: relevance for prevention of type 2 diabetes. Benef Microbes. 2011; 1(4):433-7. DOI: 10.3920/BM2010.0028. View

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Vignozzi L, Corona G . Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol. 2017; 17(1):22. PMC: 5379726. DOI: 10.1186/s12894-017-0211-9. View

MacArthur M, Hold G, El-Omar E . Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004; 286(4):G515-20. DOI: 10.1152/ajpgi.00475.2003. View

Farup P, Valeur J . Changes in Faecal Short-Chain Fatty Acids after Weight-Loss Interventions in Subjects with Morbid Obesity. Nutrients. 2020; 12(3). PMC: 7146446. DOI: 10.3390/nu12030802. View

Eberhart 2nd B, Wilson A, OKeefe S, Ramaboli M, Nesengani L . A simplified method for the quantitation of short-chain fatty acids in human stool. Anal Biochem. 2020; 612:114016. DOI: 10.1016/j.ab.2020.114016. View

Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A . The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112(4):432-41. DOI: 10.1111/bju.12118. View

10.

Pace G, Di Massimo C, De Amicis D, Vicentini C, Ciancarelli M . Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011; 37(5):617-22. DOI: 10.1590/s1677-55382011000500008. View

11.

Rooks M, Garrett W . Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16(6):341-52. PMC: 5541232. DOI: 10.1038/nri.2016.42. View

12.

Chambers E, Viardot A, Psichas A, Morrison D, Murphy K, Zac-Varghese S . Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2014; 64(11):1744-54. PMC: 4680171. DOI: 10.1136/gutjnl-2014-307913. View

13.

Miah S, Catto J . BPH and prostate cancer risk. Indian J Urol. 2014; 30(2):214-8. PMC: 3989826. DOI: 10.4103/0970-1591.126909. View

14.

Cai T, Santi R, Tamanini I, Galli I, Perletti G, Bjerklund Johansen T . Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. Int J Mol Sci. 2019; 20(15). PMC: 6696519. DOI: 10.3390/ijms20153833. View

15.

Hald S, Schioldan A, Moore M, Dige A, Laerke H, Agnholt J . Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study. PLoS One. 2016; 11(7):e0159223. PMC: 4951149. DOI: 10.1371/journal.pone.0159223. View

16.

Kim M, Benayoun B . The microbiome: an emerging key player in aging and longevity. Transl Med Aging. 2020; 4:103-116. PMC: 7437988. View

17.

Huda-Faujan N, Abdulamir A, Fatimah A, Anas O, Shuhaimi M, Yazid A . The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J. 2010; 4:53-8. PMC: 2887640. DOI: 10.2174/1874091X01004010053. View

18.

Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao J . Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC Microbiol. 2016; 16:90. PMC: 4879732. DOI: 10.1186/s12866-016-0708-5. View

19.

Yamashiro K, Tanaka R, Urabe T, Ueno Y, Yamashiro Y, Nomoto K . Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PLoS One. 2017; 12(2):e0171521. PMC: 5293236. DOI: 10.1371/journal.pone.0171521. View

20.

Moser A, Spindelboeck W, Strohmaier H, Enzinger C, Gattringer T, Fuchs S . Mucosal biopsy shows immunologic changes of the colon in patients with early MS. Neurol Neuroimmunol Neuroinflamm. 2017; 4(4):e362. PMC: 5471347. DOI: 10.1212/NXI.0000000000000362. View